Pharma’s Role in Practice Guideline Development: Achondroplasia as a Case Study
By Andrea Schelhaas, Stephanie Meredith and Katie Stoll In November 2021 under the Accelerated Approval Program, the U.S. Food and Drug Administration announced approval of Voxzogo (vosoritide), a drug developed by BioMarin for the purpose of increasing linear growth in children with achondroplasia with open growth plates (individuals who are actively growing). Achondroplasia is the …
Pharma’s Role in Practice Guideline Development: Achondroplasia as a Case Study Read More »